| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Rossi Dino A, Director
Gave 3,500 shares as a gift |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch |
| 02 Nov 2026 | 10-Q |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 |
| 16 Sep 2026 |
Form 4: Rossi Dino A, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units |
| 16 Sep 2026 |
Form 4: Sutherland Everett Rand, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units |
| 16 Sep 2026 |
Form 4: Mazzacco Catherine, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units |
| 16 Sep 2026 |
Form 4: Mason Christopher, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units |
| 16 Sep 2026 |
Form 4: Janney Daniel, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Award |
| 16 Sep 2026 |
Form 4: Gangolli Julian S, Director
Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Krishnan Suma, Director
Sold 25,000 shares ($8.98M) |
| 04 Sep 2026 |
Form 4: Krishnan Krish S, Director
Sold 25,000 shares ($8.98M) |
| 04 Sep 2026 | 144 |
| 04 Sep 2026 | 144 |
| 14 Aug 2026 |
Form 4: Rossi Dino A, Director
Gave 3,691 shares as a gift · Sold 25,000 shares ($8.23M) |
| 14 Aug 2026 | 144 |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch |
| 03 Aug 2026 | 10-Q |
Loading...